TAKEDA SUPPORTS FIRST CANADIAN PATIENT REGISTRY FOR MULTIPLE MYELOMA

September 1, 2016

Partnership with Myeloma Canada Research Network aims to optimize care for Canadians living with multiple myeloma

OAKVILLE, Ontario – September 1, 2016 – Takeda Canada Inc. announced today its support for a new registry for Canadians living with multiple myeloma with a contribution of $500,000.00 to the Myeloma Canada Research Network (MCRN) Canadian Multiple Myeloma Database – the first pan-Canadian patient registry monitoring multiple myeloma care in Canada.

Launched at the MaRS Discovery District in Toronto, the MCRN Canadian Multiple Myeloma Database is expected to be an effective tool in collecting data from people with this complex and devastating disease. Developed in full collaboration with patients and medical experts, the MCRN Canadian Multiple Myeloma Database will inform myeloma research, clinical trial development, and sound health policies for Canadian cancer patients.

“The MCRN Canadian Multiple Myeloma Database is the result of many partnerships. This innovative pan-Canadian patient research tool would not have been possible without the support of our members, fundraisers and both public and private educational grants,” says Aldo Del Col, Co-Founder and Chairman, Myeloma Canada and Myeloma Canada Research Network. “On behalf of the MRCN, I’d like to thank Takeda Canada for their commitment to this vital initiative that will directly advance patient care and clinical research.”

Takeda Canada is committed to Oncology related patient-focused initiatives and will continue to support the MCRN Canadian Multiple Myeloma Database, improving and enhancing patient care for Canadian myeloma patients overall.

“In the past decades, although progress has been made in managing multiple myeloma, there is a lack of fundamental data to demonstrate the Canadian patient experience from access to medicine to response in treatment,” said Chatrick Paul, General Manager, Takeda Canada Inc. “As Takeda Canada operates with the mind-set of always creating value to patients, we recognize the importance of investing in data and innovation in order to address access to improved care for Canadian patients with multiple myeloma across the country. We are proud of our involvement and delighted of the opportunity to partner in the MCRN Canadian Multiple Myeloma Database and look forward to seeing the results it generates.”

About the Myeloma Canada Research Network (MCRN)
The MCRN is the first and only national academic myeloma research group bringing together Canada's leading myeloma investigators from 20 centres across the country. Focusing on high-impact Phase I and II clinical trials, the MCRN brings meaningful value through its network of internationally recognized investigators who are willing to share their expertise in leading-edge myeloma research and technologies to identify new treatments and make them available through its member institutions located in both large urban and smaller communities across Canada.
About Myeloma Canada
Myeloma Canada is a non-profit, grassroots, patient-focused organization created by, and for, people living with multiple myeloma. As the only national organization exclusively devoted to the Canadian myeloma community, Myeloma Canada has been making myeloma matter since 2005. Myeloma Canada seeks to strengthen the voice of the Canadian myeloma community by working with leading myeloma researchers and clinicians, local support groups and other cancer organizations to improve the quality of life of myeloma patients, their caregivers and their families through education, awareness, advocacy and research. www.myeloma.ca

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.

Takeda Canada, located in Oakville, Ontario, is the Canadian sales and marketing organization of Takeda Pharmaceutical Company Limited. Takeda Canada is transforming to become an agile specialty pharmaceutical company, focusing on gastroenterology and oncology, while continuing to meet a number of important primary care needs. Additional information about Takeda Canada is available at takedacanada.com.